MedTrace Logo

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

NCT00825955 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 587

Last updated 2019-10-09

No results posted yet for this study

Summary

The purpose of this study is to determine if Brivanib is an effective treatment for liver cancer in patients who have failed or could not take Sorafenib

Conditions

Interventions

DRUG

Brivanib

Tablets, Oral, 800 mg, once daily, until disease progression or toxicity

OTHER

Placebo

Tablets, Oral, 0 mg, once daily, until disease progression or toxicity

PROCEDURE

Best Supportive Care

Trans-Arterial Chemo-Embolization (TACE) Therapy

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-17
Primary Completion
2011-11-15
Completion
2017-08-25

Countries

  • United States
  • Argentina
  • Belgium
  • Brazil
  • Canada
  • China
  • France
  • Germany
  • Greece
  • Hong Kong
  • India
  • Italy
  • Japan
  • Mexico
  • Puerto Rico
  • Russia
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825955 on ClinicalTrials.gov